27.09.2017

FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies

PARIS, France September 28th, 2017, Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017′s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. The announcement was made during the FierceBiotech Drug Development Forum, which took place Tuesday September 26th in Boston, MA.

Vivet Therapeutics is a biotechnology company developing novel gene therapies for rare, inherited metabolic diseases.

Vivet Team is honored to be selected as a Fierce 15 company,” said Jean-Philippe COMBAL, CEO of Vivet Therapeutics. “Our world-class team combined with best-in-class science will allow us to develop life-changing treatments for rare inherited metabolic liver disorders while addressing key challenges of gene therapy, including sustained therapeutic gene expression in young patients, adults and immune responses towards the viral vector

Vivet Therapeutics is committed to make a significant difference for patients facing rare metabolic diseases. Vivet has a strategic collaboration with Fundación para la Investigación Médica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, University of Navarra, Spain), a leading research organization in the field of Gene Therapy. Vivet also has licensed the use of novel proprietary AAV vector gene therapy technology to treat metabolic diseases and certain patent-protected Anc80 AAV gene therapy vectors from Massachusetts Eye and Ear (MEE), a teaching hospital of Harvard Medical School, Boston. Anc80 is a next-generation gene therapy technology designed to increase gene expression levels in the liver.

“We will initiate clinical development of our lead product, VTX-801 for Wilson’s Disease, in Q4 2018 and already have 3 additional programs under preclinical development” stated Jean-Philippe Combal. “Our entire team is committed to advancing our programs to generate transformative therapies for patients with high unmet medical needs.”

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s fifteenth annual Fierce 15 selection.  A complete list of “Fierce 15″ companies can be found online.

For more information, visit www.vivet-therapeutics.com

For more information, visit www.vivet-therapeutics.com

Media & Investor contact:

Thomas Daniel

Business Development Director

+33 6 68 88 38 60

info@vivet-therapeutics.com

About VTX-801:  VTX-801 is an adeno-associated virus (AAV) containing a gene coding for a functional mini-ATP7B copper transporter, that is intended to restore copper metabolism through liver cell targeting

About WiIson’s Disease:  Wilson’s disease is an inherited orphan disorder affecting approximately 1:40,000 individuals. In this condition, the physiological copper biliary elimination pathway is disrupted, leading to tissue accumulation of toxic copper levels, most notably in liver and CNS. Onset of symptoms typically occurs in teenagers or in young adults and left untreated, the condition uniformly progresses to severely debilitating complications and death. The disease is due to inactivating mutations in the gene encoding the copper transporter ATP7B.     

About Vivet Therapeutics: Vivet Therapeutics is a gene therapy biotech company with headquarters in Paris, France, dedicated to the research, development and future commercialization of gene therapy products for inherited liver disorders with high medical need. 


Download pdf English